First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Trial Profile

First-time-in-human study of CMX521 for treatment and/or prevention of norovirus infection

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs CMX521 (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2017 New trial record
    • 07 Aug 2017 According to a Chimerix media release, the company anticipates initiation of a first-time-in-human (FTIH) study for CMX521 later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top